Updates on Triple Negative Research
Wednesday, July 15, 2009 11:36 PM
From our friends at Living Beyond Breast Cancer: Medicine Shows Promise for Triple-Negative Metastatic Breast Cancer
The medicine BSI-201 given in combination with chemotherapy lengthened survival in women with triple-negative metastatic breast cancer compared to those who received chemotherapy alone.
The phase II study, presented during the plenary session of the 2009 annual meeting of the American Society of Clinical Oncology
, introduced doctors to poly ADP-ribose polymerase (PARP) inhibitors, a new class of treatments for cancer. These new medicines are believed to affect an enzyme that repairs DNA damage in cells and to enhance the effects of chemotherapy.
These findings will not immediately impact treatment options, but they represent an exciting potential new avenue for treating triple-negative and hereditary breast cancers. Meeting attendees consider the finding one of the most exciting in years and believe PARP inhibitors also may prove useful against ovarian and other cancers. Visit our Web site to read more about this study
Deborah, Albuquerque, 59, 5 year survivor!!
-Diagnosis: IDC & DCIS, Stage IIb, Grade 3, Triple Negative (3/19/08)
-No family history, BRCA 1&2 neg (Jun 08)
-A/C (4 DD Apr - Jun 08), Taxol (4 Wkly Jul-Aug 08), Taxol (2 DD Oct 08)
-Modified radical mastectomy with immediate saline implant (8/19/08), 3/12 nodes positive
-NED!!! (Nov 08)